SCHEMBL6508661

SCHEMBL6508661

Cc1n[nH]c2c1c(=O)n(CCN(C)C)c1ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 3/20 0.53
HTR6 P50406 1/20 0.46
MPO P05164 1/20 0.43
HAVCR2 Q8TDQ0 1/20 0.43
PTGER4 P35408 1/20 0.41
HTR3A P46098 1/20 0.41
TERT O14746 1/20 0.41
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
AURKA O14965 1/20 0.40
KDR P35968 1/20 0.40
AURKB Q96GD4 1/20 0.40
CDK4 P11802 1/20 0.39
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39
CCND1 P24385 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6518743 0.99 TOP2A (0.52) TOP2AHTR6MPOHAVCR2PTGER4
SCHEMBL6514910 0.85 CHEK1 (0.49) TOP2AKDM4EHTTAURKAKDR
SCHEMBL6518602 0.85 AURKA (0.41) TOP2AKDM4EMAPTAURKAKDR
SCHEMBL21067780 0.83 CYP1A2 (0.48) KDM4ESMN1; SMN2MAPTHTTRXFP1
SCHEMBL6515436 0.83 CHEK1 (0.51) KDM4EAURKAKDRAURKBMYLK
SCHEMBL6523698 0.83 TSHR (0.47) KDM4EAURKAKDRAURKBCDK4
SCHEMBL6522904 0.79 GAA (0.51) SMN1; SMN2
SCHEMBL6514357 0.79 ALDH1A1 (0.44) KDM4EMAPTHTTRXFP1AURKA
SCHEMBL6521770 0.78 HDAC3 (0.40) HTR6KDM4ESMN1; SMN2AURKAKDR
SCHEMBL6518571 0.77 HDAC3 (0.41) KDM4EHTTPIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 TOP2A 1938/4885HTR6 3259/4885MPO 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.